Regeneron's Anti-CD3 Uveitis Termination: Unidentified Safety Event Ends a First-in-Mechanism Program With Zero Recoverable Data

REGN7041's Phase 1/2 termination is a clean failure with no salvageable signal. Regeneron discontinued the anti-CD3 monoclonal antibody for non-infectious uveitis following an unfavorable benefit-risk determination after a safety event whose cause investigators could not identify — a termination that extinguishes not just this molecule but, practically speaking, the entire anti-CD3 mechanistic hypothesis in uveitis. The program ended before generating any efficacy data, any corticosteroid-sparing evidence, or any dose-optimization findings, which means there is no partial dataset to reframe, partner, or license. [1] The two therapies with established regulatory standing in non-infectious uveitis — adalimumab (anti-TNF-α, Phase 3 VISUAL I and VISUAL II RCTs) and dexamethasone intravitreal implant 700 µg (local corticosteroid, Phase 3 HURON RCT) — operate through entirely distinct mechanisms and provide no safety roadmap for CD3-targeted systemic T-cell modulation. [2] No precedent clears the mechanistic-fit bar for REGN7041: adalimumab is the closest by indication but is mechanistically inapplicable, and the PPDD analysis confirms this explicitly. [3] Anti-CD3 agents carry known class risks — cytokine release syndrome, T-cell depletion, immunosuppression-related infections — that differ fundamentally from the TNF-blockade and local steroid profiles regulators and payers have already evaluated. [4] The Australian PBAC precedent for adalimumab established that regulators will accept inferior short-term safety in uveitis only when efficacy and corticosteroid-sparing benefit are demonstrated; REGN7041 never reached the point where either could be assessed. [5] The unidentified etiology of the safety event is the sharpest risk indicator: it suggests the program could not close the loop between observed harm and mechanism, a condition that forecloses both risk mitigation and any future IND narrative for the molecule. For payers, there is no cost-effectiveness calculus to construct — the ICER question is moot. The broader Regeneron portfolio context — concurrent Phase 3 failures in itepekimab for COPD and a melanoma combination regimen — amplifies the strategic read without changing the REGN7041-specific verdict. [6] The sharpest residual risk is that the unidentified safety event may prompt regulatory or scientific scrutiny of anti-CD3 mechanisms across inflammatory indications, creating a shadow over any successor program even if a different molecule or sponsor attempts the hypothesis.

REGN7041's Phase 1/2 study was discontinued after a safety event of unidentified cause before any efficacy, corticosteroid-sparing, or dose-optimization data were produced, leaving no evidence base to evaluate and no partial signal to carry forward.